1. A 67-year-old man with hypertension, stable angina, and permanent atrial fibrillation presents for medication optimization. He is on metoprolol succinate 100 mg daily and lisinopril 10 mg daily. His BP is 156/88 mmHg and resting heart rate is 58 bpm. His physician considers adding a CCB for additional blood pressure and antianginal benefit. Which of the following represents the most dangerous prescribing error in this clinical context?
A) Adding verapamil 120 mg twice daily — combining a non-DHP CCB with a beta-blocker produces additive suppression of sinoatrial automaticity and AV nodal conduction through independent but convergent mechanisms, creating serious risk of severe bradycardia, complete heart block, and asystole; this combination is contraindicated
B) Adding amlodipine 5 mg daily — the combination of a DHP CCB with a beta-blocker substantially increases the risk of peripheral edema beyond what either agent causes alone, requiring preemptive diuretic co-prescribing
C) Adding felodipine 5 mg daily — felodipine interacts with metoprolol at the CYP2D6 level, causing dangerous metoprolol accumulation and bradycardia
D) Adding amlodipine at the 10 mg starting dose — initiating at the maximum dose risks excessive reflex tachycardia that worsens atrial fibrillation rate control
E) Adding diltiazem 60 mg three times daily — diltiazem raises metoprolol plasma levels through potent CYP2D6 inhibition, requiring a mandatory 50% metoprolol dose reduction before diltiazem can be safely added
ANSWER: A
Rationale:
The combination of a non-dihydropyridine CCB with a beta-blocker is contraindicated because both drug classes suppress cardiac conduction through independent mechanisms that converge on the same nodal tissue. Metoprolol blocks beta-1 receptors at the SA and AV nodes, reducing automaticity and conduction velocity. Verapamil or diltiazem independently block L-type calcium channels in these same nodal cells, producing additional suppression of automaticity and AV conduction. The combined suppression is additive and can produce severe bradycardia, high-degree AV block, and asystole — a life-threatening combination particularly dangerous in a patient whose resting heart rate is already 58 bpm on metoprolol alone. This is a hard contraindication, not a caution. Option E contains inaccuracy — diltiazem's interaction with beta-blockers is primarily pharmacodynamic additive nodal suppression (the contraindicated combination in option A), not a significant CYP2D6 pharmacokinetic interaction requiring preemptive dose reduction.
Option B: Option B is incorrect in its danger classification — adding a DHP CCB to a beta-blocker is acceptable and commonly done; increased edema risk is a manageable adverse effect, not a dangerous pharmacodynamic interaction.
Option C: Option C is incorrect because felodipine is not a CYP2D6 inhibitor; it undergoes CYP3A4 metabolism and does not cause metoprolol accumulation.
Option D: Option D is incorrect because DHP CCBs do not cause clinically relevant reflex tachycardia at gradual onset; starting at 5 mg is preferred for tolerability but is not a dangerous error.
2. A 74-year-old woman with isolated systolic hypertension (ISH — systolic BP consistently above 160 mmHg with normal diastolic BP) presents for initial antihypertensive therapy. Her pulse pressure is 82 mmHg. Which of the following best explains why long-acting dihydropyridine CCBs and thiazide-type diuretics are particularly well-suited to ISH in the elderly, while agents that primarily reduce cardiac output may be less effective?
A) ISH in the elderly is driven by increased cardiac output from age-related sympathetic overactivation; CCBs and diuretics reduce cardiac output more selectively than RAAS inhibitors, targeting the correct pathophysiology
B) ISH responds only to agents that reduce stroke volume; CCBs and diuretics are the only classes that selectively reduce preload without affecting afterload in elderly patients
C) ISH in the elderly is predominantly a vascular stiffness disorder — large elastic arteries lose compliance with aging, producing a wider pulse pressure as each systolic ejection generates a larger uncushioned pressure wave; CCBs reduce peripheral arteriolar resistance and favorably affect pulse wave velocity, while thiazides produce sustained vascular effects beyond natriuresis; both are supported by landmark trials in ISH (Syst-Eur, SHEP, HYVET); agents that primarily reduce cardiac output address the wrong hemodynamic component
D) ISH responds only to intravenous agents because oral agents cannot achieve the rapid onset needed to reduce systolic pressure without lowering diastolic pressure in elderly patients
E) CCBs and diuretics are preferred in ISH because they are the only classes proven to cross the blood-brain barrier and reduce central sympathetic tone, which is the primary driver of systolic hypertension in aging
ANSWER: C
Rationale:
Isolated systolic hypertension in the elderly is predominantly caused by arterial stiffness — the loss of elastic compliance in large arteries, particularly the aorta, that occurs with aging. In a normal compliant aorta, each ventricular ejection distends the vessel wall, storing energy that maintains diastolic pressure between beats. In a stiffened aorta, less distension occurs; systolic pressure rises higher with each ejection and diastolic pressure falls as the stored energy return is lost. The result is widened pulse pressure — high systolic, normal or low diastolic. Cardiac output is typically normal or reduced in elderly ISH patients, not elevated. Agents that primarily reduce cardiac output (such as beta-blockers) may lower heart rate and stroke volume but address the wrong hemodynamic component — they do not directly reduce arterial stiffness or peripheral resistance. Dihydropyridine CCBs reduce arteriolar resistance and have favorable effects on pulse wave velocity; thiazide-type diuretics produce sustained vascular effects beyond their initial natriuresis. Both have strong ISH outcome trial evidence (Syst-Eur with nitrendipine for CCBs; SHEP and HYVET with chlorthalidone and indapamide for thiazides).
Option A: Option A is incorrect because ISH is not driven by increased cardiac output.
Option B: Option B is incorrect because preload reduction alone is not the mechanism of benefit; the rationale is peripheral vascular resistance reduction.
Option D: Option D is incorrect because oral agents are entirely appropriate for chronic ISH management.
Option E: Option E is incorrect because the therapeutic advantage of CCBs and diuretics in ISH is peripheral vascular, not central sympatholytic.
3. A 61-year-old man with hypertension is started on chlorthalidone 25 mg daily. Eight weeks later he presents with acute gout in his right first metatarsophalangeal joint and a serum uric acid of 9.8 mg/dL. Which of the following most completely explains the mechanism of thiazide-associated hyperuricemia?
A) Thiazides directly inhibit xanthine oxidase in the liver, reducing uric acid catabolism and raising serum levels in a dose-dependent fashion
B) Thiazide-induced hyperaldosteronism causes uric acid retention in the proximal tubule by stimulating the URAT1 transporter through aldosterone receptor activation
C) Thiazides cause hyperuricemia solely through competition with uric acid for proximal tubular secretion via organic anion transporters, reducing urinary uric acid excretion
D) Thiazides activate the renal sympathetic nervous system, which stimulates proximal tubular urate reabsorption through adrenergic receptor-mediated URAT1 upregulation
E) Thiazides cause hyperuricemia through two complementary mechanisms: competition with uric acid for proximal tubular secretion via organic anion transporters reduces urinary uric acid output; and thiazide-induced volume contraction increases proximal tubular sodium reabsorption, with uric acid following sodium via URAT1 — both effects raising serum uric acid; losartan's URAT1-inhibiting uricosuric property can partially offset this when a thiazide must be continued
ANSWER: E
Rationale:
Thiazide-associated hyperuricemia arises from two distinct but complementary mechanisms operating at the proximal tubule. First, thiazides are organic anions secreted into the tubular lumen via the same organic anion transporters (OAT1, OAT3) responsible for uric acid secretion; when thiazide molecules occupy these transporters, less uric acid is secreted, reducing urinary uric acid output and raising serum levels. Second, thiazide-induced volume contraction activates compensatory proximal tubular sodium reabsorption; uric acid follows sodium reabsorption via the URAT1 transporter (urate-anion exchanger) in the proximal tubule — increased sodium reabsorption drives increased urate reabsorption. Both mechanisms act simultaneously and additively. The clinical implication is that patients with gout or asymptomatic hyperuricemia are at risk; if a thiazide is clinically necessary, adding losartan (which inhibits URAT1 and has uricosuric properties) provides partial pharmacological protection.
Option A: Option A is incorrect because thiazides do not inhibit xanthine oxidase; that is the mechanism of allopurinol and febuxostat.
Option B: Option B is incorrect because thiazide-induced RAAS activation is secondary to volume contraction and does not directly drive URAT1 through aldosterone receptor activation as the primary mechanism.
Option C: Option C is incorrect because it describes only one of the two mechanisms; the volume contraction-driven urate reabsorption via URAT1 is the second and often dominant mechanism.
Option D: Option D is incorrect because renal sympathetic activation is not an established mechanism of thiazide-associated hyperuricemia.
4. A 58-year-old woman with hypertension, type 2 diabetes (HbA1c 7.8%), and stage 3b CKD (eGFR 36 mL/min/1.73m2, UACR 520 mg/g) is on lisinopril 40 mg and amlodipine 10 mg daily with BP at 136/82 mmHg. Her potassium is 4.7 mEq/L. Her nephrologist proposes adding finerenone 10 mg daily. A colleague questions whether spironolactone would be equally appropriate. Which of the following best explains why finerenone is preferred over spironolactone in this specific patient?
A) Finerenone is preferred because spironolactone is absolutely contraindicated in CKD stage 3b and cannot be used at any dose in patients with eGFR below 45 mL/min/1.73m2
B) Finerenone is preferred because its cardiorenal protective efficacy in type 2 diabetes with CKD and albuminuria on background RAAS inhibition is established by FIDELIO-DKD and FIGARO-DKD, and it causes less hyperkalemia than spironolactone at equivalent cardiorenal-protective doses — clinically important in a patient whose potassium is already 4.7 mEq/L on lisinopril alone; finerenone also lacks sex hormone adverse effects
C) Finerenone is preferred because it has stronger antihypertensive efficacy than spironolactone, producing greater systolic blood pressure reduction at equivalent MR-blocking doses in diabetic CKD
D) Finerenone is preferred because spironolactone requires twice-daily dosing in CKD, which reduces adherence, while finerenone is always once daily
E) Finerenone is preferred because spironolactone's active metabolite canrenone accumulates to toxic levels in CKD stage 3b, causing cardiac arrhythmias not seen with finerenone
ANSWER: B
Rationale:
The preference for finerenone over spironolactone in this patient rests on several complementary pharmacological and clinical arguments. The primary indication for finerenone is cardiorenal protection in type 2 diabetes with CKD and significant albuminuria on background RAAS inhibition — the exact profile of this patient. FIDELIO-DKD demonstrated finerenone reduced kidney disease progression and cardiovascular events; FIGARO-DKD demonstrated reduced cardiovascular mortality. This evidence base is specific to finerenone and has not been replicated for spironolactone in diabetic CKD. The safety advantage is also critical: this patient's potassium is already 4.7 mEq/L on lisinopril alone in the context of CKD stage 3b — a borderline level at which adding spironolactone (which causes more pronounced renal MR blockade and potassium retention) carries meaningful hyperkalemia risk. Finerenone's balanced tissue distribution produces less renal potassium-retaining effect at cardiorenal-protective doses. Finally, finerenone's high MR selectivity eliminates sex hormone adverse effects.
Option A: Option A is incorrect because spironolactone is not absolutely contraindicated in CKD stage 3b; it can be used with caution, close monitoring, and at lower doses, though the risk-benefit ratio is less favorable than finerenone.
Option C: Option C is incorrect because finerenone's primary advantage is cardiorenal protection, not superior antihypertensive potency.
Option D: Option D is incorrect because spironolactone dosing frequency is not the basis for the preference.
Option E: Option E is incorrect because canrenone accumulation causing cardiac arrhythmias is not an established toxicity profile of spironolactone in CKD stage 3b at clinical doses.
5. A pharmaceutical company proposes a fixed-dose combination pill containing verapamil plus atenolol, marketed for patients with hypertension and atrial fibrillation needing both blood pressure control and ventricular rate control. A clinical pharmacologist identifies a fundamental safety problem. Which of the following best explains why this combination does not exist clinically?
A) Verapamil and atenolol are both renally eliminated and accumulate dangerously in the most common hypertensive population — those with CKD — making the combination impractical
B) Verapamil inhibits CYP2D6, causing atenolol to accumulate to toxic levels because atenolol is primarily CYP2D6-metabolized; this pharmacokinetic interaction is dose-limiting
C) Atenolol has diuretic properties in addition to beta-blockade; combining its sodium-retaining effect with verapamil's negative inotropy causes refractory edema requiring hospitalization
D) Verapamil and beta-blockers such as atenolol both suppress sinoatrial automaticity and AV nodal conduction through independent but convergent mechanisms — verapamil via L-type calcium channel blockade in nodal cells, atenolol via beta-1 receptor blockade at the same nodes; combined administration creates additive risk of severe bradycardia, high-degree AV block, and asystole; this is a hard contraindication regardless of the clinical rationale
E) Verapamil and atenolol lower blood pressure through identical mechanisms — both reduce cardiac output — offering no pharmacological synergy while doubling the risk of hypotension
ANSWER: D
Rationale:
The fundamental safety problem with combining verapamil and any beta-blocker is pharmacodynamic: both drug classes suppress the same cardiac nodal tissue through entirely independent molecular mechanisms. Verapamil blocks L-type calcium channels in sinoatrial and AV nodal cells, directly reducing automaticity and slowing conduction. Atenolol blocks beta-1 adrenoceptors at the same nodes, independently reducing catecholamine-driven automaticity and conduction. When both mechanisms operate simultaneously, their effects on nodal suppression are additive — producing severe bradycardia, high-degree AV block, and in severe cases asystole. This combination is explicitly contraindicated in all clinical guidelines. The fact that it might address two therapeutic goals simultaneously (rate control and blood pressure) is irrelevant when the combination carries a life-threatening interaction risk. This same contraindication applies to diltiazem plus any beta-blocker.
Option A: Option A is incorrect because atenolol is renally eliminated but verapamil is hepatically metabolized; differential CKD accumulation is not the primary safety concern and does not explain the clinical contraindication.
Option B: Option B is incorrect because atenolol undergoes minimal hepatic CYP metabolism — it is renally cleared without significant CYP2D6 involvement; verapamil's CYP inhibition does not meaningfully affect atenolol levels.
Option C: Option C is incorrect because atenolol has no diuretic properties and does not cause sodium retention.
Option E: Option E is incorrect because verapamil and beta-blockers do not share identical mechanisms; verapamil acts on calcium channels and atenolol on beta-1 receptors, though they converge on the same nodal tissue.
6. A 64-year-old Black woman with hypertension (BP 158/92 mmHg), stage 3a CKD (eGFR 54 mL/min/1.73m2, UACR 220 mg/g), type 2 diabetes, and no history of heart failure or coronary artery disease presents for antihypertensive optimization. She is on losartan 100 mg daily. Her potassium is 4.7 mEq/L. Her physician plans to add a second agent. Which of the following is most appropriate?
A) Amlodipine 5 mg daily — a dihydropyridine CCB is highly effective in Black patients through a renin-independent mechanism, is safe at this eGFR with no renal dose adjustment required, does not worsen potassium (critical given borderline 4.7 mEq/L on losartan in the context of CKD and diabetes), and the CCB plus RAAS inhibitor combination is supported by ACCOMPLISH evidence for cardiovascular event reduction in high-risk patients
B) Spironolactone 25 mg daily — mineralocorticoid receptor antagonism is the preferred second agent in diabetic CKD with albuminuria and provides direct antiproteinuric benefit beyond losartan
C) Chlorthalidone 12.5 mg daily — thiazide-type diuretics are preferred as the second agent in all Black patients with hypertension regardless of comorbidities
D) Verapamil 120 mg twice daily — non-DHP CCBs reduce glomerular hyperfiltration through negative chronotropy-mediated reduction in cardiac output and are specifically renoprotective in diabetic CKD
E) Furosemide 20 mg daily — loop diuretics are preferred over thiazides at eGFR 54 mL/min/1.73m2 and should replace thiazide-class agents at this GFR level
ANSWER: A
Rationale:
This patient's clinical profile creates several intersecting constraints. Her potassium of 4.7 mEq/L on losartan alone is borderline elevated; adding any agent that further raises potassium — spironolactone, eplerenone, or dose escalation of the ARB — carries meaningful hyperkalemia risk in the setting of CKD and diabetes. Amlodipine is the optimal addition: it is highly effective in Black patients through a renin-independent vascular mechanism; it is safe at any eGFR with hepatic elimination requiring no renal dose adjustment; it has no effect on potassium; it provides antihypertensive complementarity to the existing RAAS inhibitor; and the CCB plus RAAS inhibitor combination has strong evidence support from ACCOMPLISH. A thiazide-type diuretic would also be guideline-supported, but with potassium already at 4.7 mEq/L on losartan in a patient with CKD and diabetes, the thiazide-induced potassium wasting adds metabolic risk. options.
Option B: Option B is incorrect because spironolactone as a second agent in a patient with 4.7 mEq/L potassium on an ARB with CKD and diabetes creates significant hyperkalemia risk; it is appropriate as a fourth-line agent after exclusion of safer
Option C: Option C is incorrect because the blanket preference for thiazides in Black patients does not override the metabolic safety concern with borderline hyperkalemia in this specific patient.
Option D: Option D is incorrect because verapamil is not specifically renoprotective through negative chronotropy in diabetic CKD, and this mechanism claim is not established.
Option E: Option E is incorrect because thiazide-type diuretics retain adequate efficacy at eGFR 54; loop diuretics are needed when eGFR falls below approximately 30 mL/min/1.73m2.
7. A 59-year-old woman with hypertension and gout (three flares in two years; serum uric acid 8.4 mg/dL; on allopurinol) needs antihypertensive initiation. Her BP is 154/92 mmHg. She has no CKD, no diabetes, and no heart failure. Her physician wants to select an antihypertensive strategy that minimizes gout risk while providing effective blood pressure control. Which of the following is most appropriate?
A) Chlorthalidone 12.5 mg daily — at low doses the hypocalciuric effect of thiazides predominates over the hyperuricemic effect, making chlorthalidone paradoxically uricosuric at antihypertensive doses
B) Metoprolol 50 mg daily as monotherapy — beta-blockers have a uricosuric effect that lowers serum uric acid and are specifically recommended in gout-complicated hypertension
C) Losartan 50 mg daily — among available antihypertensives, losartan is uniquely uricosuric through URAT1 inhibition in the proximal tubule; initiating with losartan provides blood pressure reduction while actively lowering serum uric acid, complementing allopurinol; amlodipine can be added as a uric acid-neutral second agent if additional BP control is needed
D) Furosemide 20 mg daily — loop diuretics increase urinary uric acid excretion and are therefore preferred over all other antihypertensive agents in patients with gout
E) Lisinopril 10 mg daily — ACE inhibitors lower serum uric acid as a class effect through angiotensin II-mediated URAT1 downregulation, making them uricosuric in patients with gout
ANSWER: C
Rationale:
Losartan is the optimal initial antihypertensive in this patient. It is the only ARB — and the only antihypertensive agent in common use — with established clinically meaningful uricosuric activity, arising from inhibition of URAT1 in the proximal tubule by losartan and its active metabolite EXP3174. This property lowers serum uric acid independently of and additively with allopurinol, directly addressing both the hypertension and the hyperuricemia risk. Amlodipine is a uric acid-neutral agent that can be added as a second agent if needed without worsening gout risk. Thiazides should be avoided or used only if necessary given their uric acid-raising effect.
Option A: Option A is incorrect because no dose of a thiazide-type diuretic produces a net uricosuric effect; at all antihypertensive doses, thiazides raise serum uric acid through tubular secretion competition and volume contraction-driven urate reabsorption.
Option B: Option B is incorrect because beta-blockers do not have uricosuric properties; they are not specifically recommended in gout-complicated hypertension and would not address the uric acid concern.
Option D: Option D is incorrect because loop diuretics raise serum uric acid through the same proximal tubular competition mechanism as thiazides; they are not uricosuric and would worsen gout risk.
Option E: Option E is incorrect because ACE inhibitors do not have clinically established uricosuric activity; the angiotensin II-URAT1 mechanism is not a recognized basis for recommending lisinopril in gout-complicated hypertension.
8. A 70-year-old man with hypertension, HFrEF (EF 28%), and permanent atrial fibrillation is on carvedilol 25 mg twice daily, enalapril 10 mg twice daily, spironolactone 25 mg daily, and furosemide 40 mg daily. His BP is 148/82 mmHg. His heart rate is 64 bpm. Potassium is 4.4 mEq/L and eGFR is 52 mL/min/1.73m2. His physician wants to add an agent for further blood pressure reduction. Which of the following is the most appropriate addition?
A) Verapamil 120 mg twice daily — adding a rate-controlling non-DHP CCB will provide both BP reduction and additional rate control alongside carvedilol
B) Diltiazem 120 mg twice daily — diltiazem's intermediate cardiac selectivity makes it safer than verapamil in HFrEF and can be combined with carvedilol for rate control
C) Chlorthalidone 12.5 mg daily — switching furosemide to chlorthalidone will provide better 24-hour BP control at this eGFR
D) Hydralazine 25 mg three times daily — direct vasodilators are the preferred add-on in HFrEF when RAAS inhibition and beta-blockade are already optimized
E) Amlodipine 5 mg daily — dihydropyridine CCBs are hemodynamically neutral in HFrEF as demonstrated in V-HeFT III; amlodipine provides effective additional blood pressure reduction through vascular L-type calcium channel blockade without worsening cardiac function or creating the dangerous nodal suppression that non-DHP CCBs would produce when combined with carvedilol
ANSWER: E
Rationale:
In a patient with HFrEF on a beta-blocker, the CCB selection is critically constrained. Both verapamil and diltiazem are contraindicated in HFrEF due to negative inotropy worsening contractility, and their combination with carvedilol would additionally produce additive AV nodal suppression risking severe bradycardia and heart block. Amlodipine, a dihydropyridine with high vascular selectivity, was demonstrated hemodynamically neutral in HFrEF in V-HeFT III — it did not worsen ejection fraction, increase hospitalizations, or increase mortality. It can be added cautiously for blood pressure control. It will not interfere with carvedilol's rate control in AF (DHP CCBs do not slow AV conduction).
Option A: Option A is incorrect because verapamil is contraindicated in HFrEF due to negative inotropy and contraindicated in combination with carvedilol (a beta-blocker) due to additive AV nodal suppression.
Option B: Option B is incorrect for the same fundamental reasons — diltiazem is also contraindicated in HFrEF and the diltiazem-plus-beta-blocker combination carries the same additive nodal suppression risk.
Option C: Option C is incorrect because at eGFR 52, thiazide-type diuretics have reduced but not absent efficacy; however, this patient has HFrEF requiring furosemide for volume management — switching to chlorthalidone removes the loop diuretic that is managing his HF volume status and risks decompensation, making this inappropriate.
Option D: Option D is incorrect because hydralazine without isosorbide dinitrate is not a guideline-directed add-on for blood pressure in HFrEF in this context; the A-HeFT combination (hydralazine plus isosorbide dinitrate) has specific indications in self-identified Black patients who cannot tolerate RAAS inhibitors.
9. A 55-year-old man with treatment-resistant hypertension (BP 172/104 mmHg on lisinopril 40 mg, amlodipine 10 mg, and chlorthalidone 25 mg at maximally tolerated doses) is evaluated for a fourth-line agent. Secondary causes have been excluded. His potassium is 3.8 mEq/L, eGFR is 66 mL/min/1.73m2, and plasma renin activity (PRA) is low. He has no history of heart failure, arrhythmia, diabetes, or breast cancer. Spironolactone 25 mg daily is started. Four weeks later his BP is 138/84 mmHg, potassium is 4.8 mEq/L, and creatinine is stable — but he reports significant bilateral gynecomastia and breast tenderness. He requests an alternative. What is the most appropriate pharmacological substitution and what trade-off must be considered?
A) Switch to amiloride 5 mg daily — amiloride directly blocks ENaC and avoids all sex hormone receptor binding, providing equivalent blood pressure reduction to spironolactone in resistant hypertension
B) Switch to eplerenone 25–50 mg daily — eplerenone is a selective MRA without androgen or progesterone receptor binding, eliminating sex hormone adverse effects; the trade-off is that eplerenone is approximately 40–50x less potent than spironolactone at the mineralocorticoid receptor, requiring higher doses (up to 50 mg twice daily) and potentially providing somewhat less blood pressure reduction than spironolactone achieved in this patient
C) Switch to finerenone 20 mg daily — finerenone has no sex hormone adverse effects and has stronger evidence than eplerenone for blood pressure reduction in resistant hypertension based on its FIDELIO-DKD results
D) Switch to doxazosin 4 mg daily — alpha-1 blockers provide equivalent blood pressure reduction to spironolactone in resistant hypertension without hormonal adverse effects, as established by PATHWAY-2
E) Switch to bisoprolol 5 mg daily — PATHWAY-2 showed bisoprolol is equivalent to spironolactone in resistant hypertension and produces no sex hormone adverse effects
ANSWER: B
Rationale:
When spironolactone causes intolerable sex hormone-related adverse effects in a patient with resistant hypertension who has demonstrated a clear blood pressure response, eplerenone is the appropriate substitution. Eplerenone is a selective mineralocorticoid receptor antagonist without meaningful affinity for androgen or progesterone receptors, eliminating gynecomastia, breast tenderness, menstrual irregularities, and erectile dysfunction. The critical trade-off is potency: eplerenone is approximately 40–50x less potent than spironolactone at the MR on a per-milligram basis, requiring doses up to 50 mg twice daily to achieve mineralocorticoid blockade comparable to spironolactone 25–50 mg daily. Some patients achieve equivalent blood pressure reduction with eplerenone at appropriate doses; others have a modest attenuation of response. Potassium and blood pressure must be monitored after switching.
Option A: Option A is incorrect because amiloride blocks ENaC directly and independently of aldosterone, providing potassium-sparing benefit but not the full mineralocorticoid receptor antagonism that underlies spironolactone's efficacy in resistant hypertension; amiloride does not have PATHWAY-2 evidence in this setting.
Option C: Option C is incorrect because finerenone's primary evidence base is cardiorenal protection in diabetic CKD; it has not demonstrated superiority to eplerenone for blood pressure reduction in resistant hypertension, and its evidence in this indication specifically is limited compared to eplerenone.
Option D: Option D is incorrect because PATHWAY-2 showed doxazosin was inferior to spironolactone — not equivalent; switching to doxazosin risks loss of the blood pressure control achieved.
Option E: Option E is incorrect because PATHWAY-2 showed bisoprolol was also inferior to spironolactone; it is not equivalent and switching risks loss of BP control.
10. A 62-year-old woman with hypertension is on amlodipine 10 mg and losartan 100 mg daily with excellent blood pressure control but significant bilateral ankle edema. BNP is normal. DVT has been excluded. Her physician correctly identifies the mechanism as CCB-associated capillary hydrostatic pressure imbalance and considers pharmacological options. Which of the following management steps most directly addresses the mechanism while preserving blood pressure control?
A) Add furosemide 20 mg daily — the loop diuretic will reduce circulating volume, lowering capillary hydrostatic pressure system-wide and resolving the edema within two weeks
B) Switch amlodipine to verapamil — non-DHP CCBs do not cause peripheral edema because their cardiac rate-slowing effect prevents the reflex arteriolar dilation responsible for amlodipine edema
C) Reduce losartan to 50 mg daily to create pharmacological space for adding a thiazide diuretic, which will directly counteract the sodium accumulation in edematous tissues
D) Reduce amlodipine from 10 mg to 5 mg (edema is dose-dependent; reducing the dose reduces the degree of arteriolar-venous pressure imbalance) or switch to felodipine (lower edema rate than amlodipine at equivalent antihypertensive doses due to its higher vascular selectivity), while maintaining losartan at maximum dose to preserve the venodilatory counteraction of CCB edema
E) Discontinue losartan and add chlorthalidone — thiazide diuretics are the only agents proven to directly reduce CCB-associated interstitial edema through their natriuretic mechanism
ANSWER: D
Rationale:
CCB-associated peripheral edema is dose-dependent and results from preferential arteriolar dilation without matched venodilation, raising capillary hydrostatic pressure in dependent tissues. The two most direct pharmacological strategies for managing this without discontinuing the CCB are: (1) reducing the amlodipine dose (10 mg → 5 mg), which reduces the degree of arteriolar dilation and therefore the capillary hydrostatic pressure imbalance — though this must be weighed against possible reduction in blood pressure control; or (2) switching to felodipine, which has a somewhat higher vascular selectivity than amlodipine and a lower rate of peripheral edema at equivalent antihypertensive doses in comparative studies. In both cases, maintaining losartan at maximum dose is important because the RAAS inhibitor's venodilatory and efferent arteriolar dilating effects directly counteract the CCB edema mechanism.
Option A: Option A is incorrect because furosemide addresses sodium-mediated volume overload; CCB edema is a capillary hydrostatic pressure imbalance without sodium excess — loop diuretics have limited and non-mechanistically appropriate efficacy for this edema type.
Option B: Option B is incorrect because switching to verapamil introduces the risk of the non-DHP plus beta-blocker combination if the patient is on a beta-blocker, and more importantly, non-DHP CCBs are contraindicated if HFrEF is ever a concern; the premise that non-DHP CCBs do not cause edema is also somewhat incorrect — they can cause edema, though less commonly than DHP CCBs.
Option C: Option C is incorrect because reducing the RAAS inhibitor removes the agent that directly counteracts the CCB edema mechanism, and thiazide diuretics do not directly address the hemodynamic mechanism.
Option E: Option E is incorrect for the same reason — discontinuing the RAAS inhibitor eliminates the key mechanistic counteraction to CCB edema.
11. A 68-year-old woman with hypertension and bilateral adrenal hyperplasia causing primary aldosteronism has been on spironolactone 50 mg daily for 18 months with excellent blood pressure control (BP 124/76 mmHg) and normalized potassium. She is now planning to undergo elective surgery requiring general anesthesia. Her anesthesiologist asks whether spironolactone should be held perioperatively. Her surgeon asks whether she could be switched to a "simpler" antihypertensive temporarily. Which of the following best explains the pharmacological consideration in her perioperative management?
A) Spironolactone should generally be continued perioperatively in primary aldosteronism because its discontinuation removes the mineralocorticoid receptor blockade that is controlling her volume-dependent hypertension; without it, sodium retention and hypertension will recur within days given the ongoing autonomous aldosterone excess from bilateral adrenal hyperplasia; switching to a standard antihypertensive that does not target the MR will not adequately control her aldosterone-mediated volume expansion
B) Spironolactone should be held 48 hours before surgery because its potassium-sparing effect combined with intraoperative fluids causes dangerous hyperkalemia that is not seen with other antihypertensives in the perioperative period
C) Spironolactone can be switched to amlodipine preoperatively without loss of blood pressure control because CCBs are equally effective at reversing the volume expansion of primary aldosteronism through their renin-independent vascular mechanism
D) Spironolactone must be tapered over four weeks before surgery because abrupt discontinuation causes a withdrawal syndrome with rebound aldosterone surge and hypertensive crisis similar to clonidine withdrawal
E) Spironolactone can be safely held for up to 30 days without loss of blood pressure control due to its very long half-life and tissue accumulation in adrenal aldosterone-secreting cells
ANSWER: A
Rationale:
Primary aldosteronism with bilateral adrenal hyperplasia involves autonomous, ongoing aldosterone excess that is not suppressible by normal physiological feedback. Without spironolactone blocking the mineralocorticoid receptor, aldosterone continuously drives sodium retention, volume expansion, potassium wasting, and hypertension. This is not a condition that resolves on drug holidays — the adrenal glands continue producing excess aldosterone regardless. Switching to a standard antihypertensive (amlodipine, lisinopril, beta-blocker) addresses downstream blood pressure consequences but does not block the primary pathological driver — unchecked mineralocorticoid receptor activation. The result would be worsening volume expansion, rising blood pressure, and hypokalemia within days. Spironolactone should generally be continued through the perioperative period; if necessary, the anesthesiology team should be aware of its effects on potassium handling and plan fluid and electrolyte management accordingly.
Option B: Option B is incorrect because while potassium monitoring is appropriate perioperatively in patients on MRAs, hyperkalemia from spironolactone in the perioperative period is manageable and is not a standard indication to hold it — uncontrolled aldosterone excess from holding it is the greater risk.
Option C: Option C is incorrect because amlodipine does not reverse aldosterone-mediated volume expansion; it reduces vascular resistance but does not block the mineralocorticoid receptor.
Option D: Option D is incorrect because spironolactone does not cause a withdrawal syndrome with adrenal rebound — aldosterone withdrawal syndromes are not a feature of MRA discontinuation in the way clonidine rebound is a feature of sympatholytic discontinuation.
Option E: Option E is incorrect because spironolactone's half-life is not long enough to provide a 30-day drug holiday effect.
12. The HYVET trial studied antihypertensive therapy in patients aged 80 or older with systolic BP of 160 mmHg or above. Which of the following correctly describes the trial design, primary finding, and its significance for prescribing in the very elderly?
A) HYVET compared indapamide to amlodipine in patients over 80 and found amlodipine superior for all endpoints, establishing CCBs as the preferred first-line agent in the very elderly
B) HYVET tested intensive versus standard blood pressure targets (systolic 120 vs. 140 mmHg) in patients over 80 and found intensive targets caused excess harm through falls and cognitive decline
C) HYVET randomized patients aged 80 or older to indapamide-based therapy (with or without perindopril) versus placebo; the trial was stopped early due to clear benefit in the active treatment arm, with reductions in stroke (~30%), all-cause mortality (~21%), and heart failure (~64%); this established definitively that antihypertensive treatment benefits extend into the ninth decade and beyond, countering the prior uncertainty about whether very elderly patients should be treated
D) HYVET found that patients aged 80 or older with BP above 160 mmHg had no cardiovascular benefit from antihypertensive treatment, establishing that treatment should be withheld after age 80 to avoid harm from orthostatic hypotension and falls
E) HYVET compared thiazide therapy to RAAS inhibitor therapy in patients over 80 and found no difference in outcomes, confirming that drug class selection is irrelevant in the very elderly as long as blood pressure is controlled
ANSWER: C
Rationale:
HYVET enrolled 3,845 patients aged 80 or older with sustained systolic blood pressure of 160 mmHg or above and randomized them to indapamide 1.5 mg (with or without perindopril 2–4 mg) versus placebo. The trial was stopped early — not due to harm, but because benefit in the active treatment group was clear and compelling. The primary endpoint (fatal or nonfatal stroke) was reduced by approximately 30%; all-cause mortality by approximately 21%; and heart failure by approximately 64% — a striking result that settled a long-standing clinical uncertainty. Prior to HYVET, many clinicians were reluctant to treat hypertension aggressively in the very elderly due to concerns about orthostatic hypotension, falls, cognitive effects, and the possibility that lowering blood pressure in patients with stiffened arteries might reduce cerebral perfusion. HYVET demonstrated that these concerns, while requiring clinical attention, should not prevent evidence-based treatment in this population.
Option A: Option A is incorrect because HYVET was placebo-controlled, not a head-to-head comparison of indapamide versus amlodipine.
Option B: Option B is incorrect because that describes elements of SPRINT and ACCORD rather than HYVET; HYVET was not an intensive versus standard target trial.
Option D: Option D is incorrect — HYVET showed clear benefit, not absence of benefit.
Option E: Option E is incorrect because HYVET was placebo-controlled and did not compare drug classes.
13. A 72-year-old man with hypertension, atrial fibrillation on rate control, and stage 3a CKD (eGFR 56 mL/min/1.73m2) presents with BP 164/90 mmHg. He is on metoprolol succinate 100 mg daily and losartan 100 mg daily. His potassium is 4.8 mEq/L. His resting heart rate is 62 bpm. His physician considers adding a third antihypertensive agent. Which of the following is most appropriate given the full clinical picture?
A) Add verapamil 120 mg twice daily — non-DHP CCBs provide additional rate control in AF alongside metoprolol and reduce blood pressure through vasodilation
B) Add amlodipine 5 mg daily — a DHP CCB is the safest CCB addition in a patient on a beta-blocker (no risk of additive AV nodal suppression), is effective across this patient's demographic and CKD stage, requires no renal dose adjustment, and avoids worsening his borderline potassium; it provides antihypertensive benefit without affecting rate control or potassium
C) Add chlorthalidone 12.5 mg daily — thiazide-type diuretics are preferred as the third agent in all patients with CKD and AF regardless of potassium status
D) Add spironolactone 25 mg daily — low-renin resistant hypertension is common in older patients and spironolactone should be added as the third agent whenever potassium allows
E) Add diltiazem 120 mg twice daily — diltiazem's intermediate cardiac selectivity makes it safer than verapamil when combined with metoprolol for dual rate control in AF
ANSWER: B
Rationale:
This patient's clinical profile creates specific constraints on the choice of third antihypertensive agent. He is on metoprolol (a beta-blocker), which absolutely precludes adding any non-dihydropyridine CCB — verapamil or diltiazem — due to the life-threatening risk of additive AV nodal suppression causing severe bradycardia or complete heart block. His resting heart rate of 62 bpm reinforces this concern. His potassium of 4.8 mEq/L on losartan with CKD argues against adding a potassium-retaining agent (spironolactone) or relying heavily on a potassium-wasting agent (thiazide) without careful monitoring. Amlodipine is the optimal choice: it is a DHP CCB with no AV nodal effects (safe to combine with metoprolol), requires no renal dose adjustment at eGFR 56, has no effect on potassium, and provides effective antihypertensive benefit through a renin-independent vascular mechanism.
Option A: Option A is incorrect because verapamil combined with metoprolol is contraindicated due to additive AV nodal suppression — this is the single most dangerous prescribing error in this scenario.
Option C: Option C is incorrect because while a thiazide is guideline-supported, the blanket statement that it is preferred regardless of potassium status ignores this patient's borderline potassium of 4.8 mEq/L on losartan; amlodipine avoids this metabolic risk.
Option D: Option D is incorrect because this patient does not meet criteria for resistant hypertension (BP uncontrolled on three optimized agents including a diuretic); spironolactone is a fourth-line agent and adding it as a third agent with potassium already at 4.8 mEq/L on losartan and CKD creates hyperkalemia risk.
Option E: Option E is incorrect because diltiazem plus metoprolol carries the same contraindicated additive AV nodal suppression risk as verapamil plus metoprolol — both non-DHP CCBs are contraindicated with beta-blockers.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.